What happens when you take venlafaxine with St. John's wort?
Venlafaxine (Effexor, Effexor XR) is a serotonin-norepinephrine reuptake inhibitor (SNRI) used for major depressive disorder, generalized anxiety disorder, social anxiety disorder, and panic disorder. At lower doses it behaves much like an SSRI, blocking the serotonin transporter; at higher doses (typically above 150 mg per day) it also blocks the norepinephrine transporter. St. John's wort (Hypericum perforatum) is a botanical product whose key active constituents, especially hyperforin, inhibit reuptake of serotonin, norepinephrine, and dopamine.
Combining the two stacks reuptake inhibition - both on serotonin and, at higher venlafaxine doses, on norepinephrine. This can push synaptic serotonin to levels associated with serotonin syndrome: agitation, confusion, tremor, clonus, hyperreflexia, sweating, fever, tachycardia, hypertension, and in severe cases hyperthermia, seizures, rhabdomyolysis, and death. Case reports of SSRI/SNRI plus St. John's wort have included venlafaxine, and the mechanism is biologically clear.
There is a pharmacokinetic layer as well. St. John's wort is a strong inducer of CYP3A4, CYP2C9, CYP2C19, and P-glycoprotein. Venlafaxine is metabolized primarily by CYP2D6 to its active metabolite O-desmethylvenlafaxine, with smaller contributions from CYP3A4 and CYP2C19. Chronic St. John's wort use can therefore alter the parent-to-metabolite ratio and reduce overall exposure, blunting antidepressant effect even as serotonin tone rises.
Why is this important?
Venlafaxine has dose-dependent serotonergic and noradrenergic activity. At low to moderate doses (37.5-150 mg per day) it is primarily serotonergic. At higher doses (225 mg or more per day), strong norepinephrine reuptake inhibition is layered on. Patients on higher-dose venlafaxine therefore have multiple sympathomimetic and serotonergic effects stacking with the supplement's own serotonin-raising activity. The clinical presentation of serotonin syndrome in this setting can be particularly autonomic, with marked tachycardia and hypertension.
Venlafaxine is also notable for a difficult discontinuation profile. Even a single missed dose can trigger dizziness, electric-shock sensations, nausea, and anxiety. This raises management complexity: a patient cannot simply stop venlafaxine cold turkey to make space for St. John's wort, and most clinicians would discourage the swap anyway given the supplement's variable potency and lack of dose standardization.
The U.S. National Center for Complementary and Integrative Health (NCCIH) explicitly warns that combining St. John's wort with antidepressants can cause potentially life-threatening serotonin syndrome, and major drug-interaction databases classify venlafaxine plus St. John's wort as a major interaction to avoid.
What should you do?
If you take venlafaxine, do not start St. John's wort. If you currently take both, contact your prescriber promptly. Do not stop venlafaxine on your own - discontinuation can be severe, especially from immediate-release formulations. Seek emergency care if you have tremor, fever, fast heart rate, sweating, agitation, twitching, or muscle stiffness, and bring the supplement bottle so clinicians can see the product and dose.
If you and your prescriber decide to discontinue venlafaxine, taper it carefully (often switching to the XR form first, then tapering by small increments over weeks to months). Allow at least one to two weeks of washout before considering any new serotonergic agent. Most psychiatrists would not recommend St. John's wort as a replacement for prescription SNRI therapy in moderate to severe illness.
Disclose every supplement, tea, and herbal product to your prescribing clinician and pharmacist. Be alert to St. John's wort in multi-ingredient products labeled for stress, sleep, mood, women's wellness, or hot flashes - it sometimes appears only under its Latin name (Hypericum perforatum) or a regional name (Johanniskraut, millepertuis, hierba de San Juan).
Which specific products are affected?
This warning covers all forms of venlafaxine: Effexor, Effexor XR, and authorized generics in immediate-release tablet, extended-release capsule, and extended-release tablet formats. The interaction also extends to desvenlafaxine (Pristiq, Khedezla), which is venlafaxine's active metabolite marketed as a separate SNRI. On the supplement side, the warning applies to any Hypericum perforatum product: standardized extracts (often labeled 0.3% hypericin or 3-5% hyperforin), capsules, tablets, tinctures, teas, and combination products.
Other serotonergic agents that compound risk include SSRIs, tramadol, triptans, fentanyl, MDMA, dextromethorphan, linezolid, MAO inhibitors, lithium, tryptophan, and 5-HTP. Patients on venlafaxine should treat any new serotonergic exposure as worth raising with their prescriber.
The bottom line
Venlafaxine and St. John's wort should not be combined. The pharmacodynamic risk of serotonin syndrome is real, and St. John's wort can additionally reduce venlafaxine exposure through CYP induction. Treat St. John's wort as off-limits while on venlafaxine, and disclose every supplement and herbal product to your healthcare team.